isoxazoles has been researched along with 3-methyl-n-(3-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)isoxazole-5-carboxamide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Carmeli, S; Elad-Sfadia, G; Haklai, R; Kloog, Y; Mashiach-Farkash, E; Rak, R; Wolfson, HJ | 1 |
| Kloog, Y; Rak, R | 1 |
| Demyanenko, SV; Uzdensky, A | 1 |
3 other study(ies) available for isoxazoles and 3-methyl-n-(3-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)isoxazole-5-carboxamide
| Article | Year |
|---|---|
Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton.
Topics: Actin Cytoskeleton; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferation; Drug Synergism; Farnesol; Humans; Isoxazoles; Lim Kinases; Mice; Mice, Knockout; Neurofibromin 1; Protein Kinase Inhibitors; Salicylates | 2012 |
Targeting LIM kinase in cancer and neurofibromatosis.
Topics: Animals; Antineoplastic Agents; Benzamides; Humans; Isoxazoles; Lim Kinases; Mice; Neoplasms; Neurofibromatosis 1 | 2014 |
LIM kinase inhibitor T56-LIMKi protects mouse brain from photothrombotic stroke.
Topics: Animals; Benzamides; Brain; Brain Ischemia; Disease Models, Animal; Isoxazoles; Lim Kinases; Mice; Stroke | 2021 |